Why Perimeter Solutions (PRM) Is Back on Investor Radars

Perimeter Solutions (PRM) has drawn fresh attention after reporting 2025 sales growth of 16% and spotlighting momentum in its specialty products segment, alongside a US$685 million purchase of Medical Manufacturing Technologies.

The share price has moved higher over the past month, with a 1 month share price return of 11.95%. However, the year to date share price return of 7.38% and 90 day share price return of 8.28% suggest momentum has cooled. At the same time, the 1 year total shareholder return of 155.57% and 3 year total shareholder return of about 2.5x indicate a very strong longer term payoff for investors who stayed in.

If Perimeter’s recent acquisition and specialty products growth have your attention, it can be a good moment to widen your watchlist and check out 18 top founder-led companies

With PRM trading at US$25.48, a reported intrinsic discount of about 50% and a roughly 28% gap to the current analyst price target, investors now face a key question: is there real upside left, or is the market already pricing in future growth?

Preferred Price-to-Sales Ratio of 5.8x: Is It Justified?

On current numbers, Perimeter Solutions looks expensive on a P/S of 5.8x, especially when set against both the Chemicals industry and fair value estimates.

The P/S ratio compares the company’s market value to its revenue, giving you a shorthand view of how much investors are paying for each dollar of sales. For a business with US$652.9 million in revenue, a higher P/S often implies the market is willing to pay up for expected growth, margins, or cash generation that are not yet fully visible in reported earnings, particularly for a company that is still loss making.

Here, PRM’s P/S of 5.8x stands well above the US Chemicals industry average of 1.1x and also sits above the estimated fair P/S of 4.3x. That is a steep premium. The fair ratio suggests a level the market could potentially move toward if expectations cool or growth does not match the optimism currently implied by the share price.

Result: Price-to-sales of 5.8x (OVERVALUED)

However, the premium P/S, the ongoing net loss of US$206.4 million, and the recent 90 day and year to date share price declines could all challenge the bullish case.

Another View: DCF Points the Other Way

While the 5.8x P/S ratio paints PRM as expensive, the SWS DCF model suggests the opposite. The share price of US$25.48 is about 50% below an estimated future cash flow value of US$51.11. That split raises a simple question for you: is price tracking sales or cash flows?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Perimeter Solutions for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With the numbers sending mixed signals, the real question is how you weigh the risks against the potential rewards. Take a closer look at the full breakdown of 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If PRM has sharpened your interest, do not stop here. Broaden your opportunity set now so you are not relying on a single story.

• Target resilient compounding potential by scanning companies that screen as 58 high quality undervalued stocks.
• Strengthen your income focus by reviewing a curated list of 11 dividend fortresses.
• Protect your downside by zeroing in on 72 resilient stocks with low risk scores that aim to keep volatility in check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.